Humana Inc. (NYSE:HUM – Get Free Report) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 4,380,000 shares, a growth of 15.9% from the October 15th total of 3,780,000 shares. Currently, 3.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,230,000 shares, the days-to-cover ratio is presently 2.0 days.
Analyst Ratings Changes
HUM has been the topic of a number of research analyst reports. Piper Sandler downgraded Humana from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $392.00 to $274.00 in a research report on Thursday, October 3rd. Barclays increased their price objective on shares of Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. UBS Group lowered their price target on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, October 4th. Truist Financial decreased their price objective on Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a research note on Friday, October 11th. Finally, Royal Bank of Canada cut their target price on shares of Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Twenty equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Humana currently has a consensus rating of “Hold” and a consensus target price of $315.86.
View Our Latest Research Report on Humana
Institutional Investors Weigh In On Humana
Humana Trading Down 2.6 %
HUM opened at $275.67 on Monday. Humana has a 1-year low of $213.31 and a 1-year high of $527.18. The company has a fifty day moving average price of $281.36 and a two-hundred day moving average price of $331.94. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market cap of $33.19 billion, a P/E ratio of 24.42, a price-to-earnings-growth ratio of 2.17 and a beta of 0.52.
Humana (NYSE:HUM – Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. The company had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Analysts predict that Humana will post 15.86 EPS for the current fiscal year.
Humana Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is 31.36%.
Humana Company Profile
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories
- Five stocks we like better than Humana
- What is the S&P 500 and How It is Distinct from Other Indexes
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Retail Stocks Investing, Explained
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What is the S&P/TSX Index?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.